Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AT-0174 by Antido Therapeutics (Australia) for Non-Small Cell Lung Carcinoma: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Non-Small Cell Lung Carcinoma. According...
AT-0174 by Antido Therapeutics (Australia) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...
AT-0174 by Antido Therapeutics (Australia) for Peritoneal Cancer: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Peritoneal Cancer. According to GlobalData,...
AT-0174 by Antido Therapeutics (Australia) for Epithelial Ovarian Cancer: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Epithelial Ovarian Cancer. According to...
AT-0174 by Antido Therapeutics (Australia) for Fallopian Tube Cancer: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Fallopian Tube Cancer. According to...
AT-0174 by Antido Therapeutics (Australia) for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According...
AT-0174 by Antido Therapeutics (Australia) for Oligodendroglioma: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Oligodendroglioma. According to GlobalData, Phase...
AT-0174 by Antido Therapeutics (Australia) for Thyroid Cancer: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Thyroid Cancer. According to GlobalData,...
AT-0174 by Antido Therapeutics (Australia) for Anaplastic Astrocytoma: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData,...
AT-0174 by Antido Therapeutics (Australia) for Glioblastoma Multiforme (GBM): Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Glioblastoma Multiforme (GBM). According to...
AT-0174 by Antido Therapeutics (Australia) for Solid Tumor: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Solid Tumor. According to GlobalData,...
AT-0174 by Antido Therapeutics (Australia) for Endometrial Cancer: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Endometrial Cancer. According to GlobalData,...
AT-0174 by Antido Therapeutics (Australia) for Melanoma: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Melanoma. According to GlobalData, Phase...
AT-0174 by Antido Therapeutics (Australia) for Small-Cell Lung Cancer: Likelihood of Approval
AT-0174 is under clinical development by Antido Therapeutics (Australia) and currently in Phase I for Small-Cell Lung Cancer. According to...